Rapamycin-resistant diffuse large B-cell lymphoma cell lines
Summary:
Analysis of diffuse large B-cell lymphoma (DLBCL) cell lines resistant to rapamycin, the prototypical mTOR (mammalian Target Of Rapamycin) inhibitor. The mTOR pathway is constitutively activated in DLBCL. Results provide insight into mechanisms of resistance to mTOR inhibition in DLBCL.
GPL6244:
[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version]
Citation:
Petrich AM, Leshchenko V, Kuo PY, Xia B et al. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Clin Cancer Res 2012 May 1;18(9):2534-44. PMID: 22338016
